Clinical Trials Browser

Phase 2 × Selective Estrogen Receptor Modulators × 90 days × Clear all

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms